Scientists test new drug for multiple sclerosis treatment
Northwestern University: ibudilast slowed the rate of brain atrophy in multiple sclerosis by 48% — a trial in 255 patients.
Northwestern University: ibudilast slowed the rate of brain atrophy in multiple sclerosis by 48% — a trial in 255 patients.
Ibudilast — one of the most promising drugs against multiple sclerosis — has completed the second phase of clinical trials. Testing was conducted by Northwestern University. The drug was shown to significantly reduce the rate of brain tissue destruction.
As part of the latest study, the drug was tested on 255 volunteers with primary and secondary multiple sclerosis. Half received ibudilast, while the rest were given a placebo. Over nearly two years, the drug reduced the rate of brain atrophy progression by 48% in the main group compared with placebo.
This means the agent helps to manage the severe symptoms of the disease. As for side effects, gastrointestinal disturbances, headaches, and depression were most commonly reported.
Book a visit — we will pick a convenient time.